Evidence map›Paper›PMID 40266405›Full record

ReviewMetabolic brain disease2025

Butyrate: a key mediator of gut-brain communication in Alzheimer's disease.

Faeze Kachoueiyan, Niosha Yahyavi Kalkhoran, Anousha Yahyavi Kalkhoran, Ashishkumar Kyada, M M Rekha, Kamlesh Chaudhary, Amit Barwal, Fadhil Faez Sead, Kamal Kant Joshi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Biomolecules · 2026
    Review
  6. Review
  7. Review
  8. Review
  9. Frontiers in pharmacology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Faeze KachoueiyanDepartment of Biology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Niosha Yahyavi KalkhoranDepartment of Biology, Biological Sciences College, Varamin-Pishva Branch, Islamic Azad University, Varamin, Iran.
Anousha Yahyavi KalkhoranDepartment of Biology, Biological Sciences College, Varamin-Pishva Branch, Islamic Azad University, Varamin, Iran.
Ashishkumar KyadaDepartment of Pharmacy, Faculty of Health Sciences, Marwadi University Research Center, Marwadi University, Rajkot, 360003, Gujarat, India. ashishkumar.kyada.edu@gmail.com.
M M RekhaDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
Kamlesh ChaudharyDepartment of Neurology, National Institute of Medical Sciences, NIMS University Rajasthan, Jaipur, India.
Amit BarwalChandigarh Pharmacy College, Chandigarh Group of Colleges-Jhanjheri, Mohali, 140307, Punjab, India.
Fadhil Faez SeadDepartment of Dentistry, College of Dentistry, The Islamic University, Najaf, Iraq.
Kamal Kant JoshiDepartment of Allied Science, Graphic Era Hill University, Dehradun, 248002, Uttarakhand, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD), a prevalent neurodegenerative disorder, represents a significant global health challenge, characterized by cognitive decline and neuroinflammation. Recent investigations have highlighted the critical role of the gut-brain axis in the pathogenesis of AD, particularly focusing on the influence of short-chain fatty acids (SCFAs), metabolites produced by the gut microbiota through the fermentation of dietary fiber. Among SCFAs, butyrate has emerged as a crucial mediator, positively impacting various pathological processes associated with AD, including epigenetic regulation, neuroinflammation modulation, maintenance of the blood-brain barrier (BBB), enhanced intestinal integrity, regulation of brain metabolism, and interference with amyloid protein formation as well as tau protein hyperphosphorylation. Furthermore, distinctions in butyrate profile and microbial communities have been observed between AD patients and healthy individuals, underscoring the importance of gut microbiota in AD progression. This review summarizes the current understanding of the many functions of butyrate in reducing the consequences of AD and emphasizes the possibility of addressing the gut microbiota as a therapeutic approach to managing AD.

Indexed as

Alzheimer DiseaseBrainBrain-Gut AxisButyratesGastrointestinal MicrobiomeAnimalsBlood-Brain BarrierHumansButyratesAlzheimer's diseaseButyrateGut microbiotaNeurodegenerative diseaseSCFAs

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.